| RANI 1.64 248.27% | BYND 0.6456 24.15% | SOXS 4.06 1.00% | YYAI 0.121 0.83% | YDKG 0.057 -40.50% | SQQQ 14.89 -1.85% | BITF 5.01 -5.11% | NVDA 183.22 0.78% | TSLL 20.17 4.83% | BBAI 7.42 -3.64% | INTC 37.01 0.46% | RGTI 46.38 -3.31% | XRTX 1.1 29.41% | GDXD 0.7214 20.23% | F 11.92 1.53% | PLUG 3.4 -2.30% | ARTV 6.01 116.97% | BURU 0.343 0.85% | IBIT 60.47 -1.56% | SOXL 40.29 -0.69% | TSLA 439.31 2.46% | DNN 2.92 -5.50% | SPY 664.39 0.57% | SLV 46.99 -4.43% | BBD 3.3 1.23% | IONZ 3.7 7.56% | HBAN 15.5 0.85% | OPEN 7.16 0.70% | NVTS 14.66 -6.21% | CAN 1.6 -4.19% | NIO 6.75 -1.17% | JDST 3.8 15.85% | TQQQ 103.99 1.90% | GDX 78.73 -6.76% | RXRX 5.86 -7.86% | HYG 80.72 0.26% | QQQ 603.93 0.66% | HIMS 49.78 -15.84% | TLRY 1.56 1.30% | ULTY 5.15 -1.90% | BTG 5.55 -6.49% | HPE 22.96 2.04% | LAES 6.67 4.87% | RGTZ 11.97 6.59% | GLD 388.88 -1.91% | ETHD 4.09 2.25% | ELBM 2.22 35.37% | TSLQ 7.89 -4.94% | ETHA 28.94 -1.03% | TZA 8 2.17%
Article image

Comparative Analysis of Avenue Therapeutics, Revelation Biosciences, and Ensysce Biosciences

Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focused on developing and commercializing therapies for the treatment of pain. Currently, ATXI's stock price is $0.36, with a target price of $0.20. This target price is 45.13% lower than the current market price, reflecting a negative outlook from investment analysts.

In contrast, Revelation Biosciences, Inc. (REVB) has a current stock price of $2.51 and a DCF valuation of $3.79. This results in a price percentage difference of 50.98%, indicating a potential for growth. REVB's market cap stands at $5,094,795, but it has a negative EPS of -246.21 and a PE ratio of -0.25, suggesting financial challenges despite the positive price outlook.

Ensysce Biosciences, Inc. (ENSC) has a stock price of $2.36, with a DCF valuation of $1.83, leading to a price percentage difference of -22.36%. ENSC's market cap is $5,594,852, and it has an EPS of 110.31. ENSC offers a dividend yield of 20.40%, which may attract income-focused investors.

Published on: July 14, 2025